Ultrasonographic quantification of the endometrium echogenicity and heterogeneity in canine physiological and pathological conditions using computer-assisted analysis.

The aims of this study were: To ultrasonographically describe and compare endometrial echogenicity and heterogeneity using digital analysis in normal and bitches suffering from pyometra, cystic endometrial hyperplasia (CEH) and endometritis; and to evaluate the effect of clinical, bacteriological and histopathological uterine parameters on endometrial echogenicity and heterogeneity. Forty-one post pubertal intact bitches were included. According to clinical, ultrasonographic, anatomopathological and histopathological uterine evaluation, the animals were classified as: Pyometra (PYO; n=6); CEH (n=8); Endometritis (END; n=13); Normal group (NG; n=14). Endometrial images were analyzed with ImageJ software to obtain echogenicity and heterogeneity, represented as the mean gray value (MGV) and standard deviation of gray (SDG), respectively. The effect of the group, clinical, bacteriological, ultrasonographic and histological variables on MGV and SDG were analyzed by a generalized linear model. PYO exhibited higher MGV (P<0.01) and SDG (P<0.01) than the other groups. No differences were found among CEH, END and NG for both parameters (P>0.1). Body weight decreased MGV (P<0.01), while increasing degrees of inflammatory reaction (P<0.01), edema (P<0.01), hemorrhages (P<0.01) and vascular congestion (P<0.01) were associated with higher MGV. Inflammatory reaction (P<0.01) and ulceration (P<0.01) increased SDG. Ultrasonographic images evaluated using computer assisted image analysis were useful to differentiate pyometra from other uterine conditions in dogs. However, this technique could not differentiate among CEH, END and NG. Uterine echogenicity and echotexture, which clearly represent the different histopathological patterns, contribute to the diagnosis of the definite diagnosis of some canine uterine diseases.

Evaluation of Long-Term Effects of the Gonadotrophin-Releasing-Hormone Antagonist Acyline on Domestic-Cat Growth.

Acyline contraception has been described in cats, but few data are available on the drug's long-term effect on growth. The relevant data cover until puberty with no radiographic description. We investigated the radiographic parameters throughout bone growth in order to more completely determine the drug's safety. Thirteen male and 12 female cats were studied, with the kittens being randomly assigned to one of the following groups within the first 24 hours of birth: ACY, subcutaneous acyline, 33 µg/100 g, which injection was repeated weekly until age 3 months; or CO, untreated control. Body measurements were recorded weekly and radiographic parameters obtained from monthly radiographs of the antebrachium. In the ACY and CO male and female kittens, the body weight, withers height, and body length plus the age at the end of body growth and radial growth remained similar throughout the study (P> .05). Both female groups finished radial growth before the males (P< .05). The ACY females evidenced a longer radial length between the eighth and 28th weeks (P< .05). All groups closed their proximal and distal physes within the normal ranges described for the species. The bone-cortex width was lower in the ACY vs. the CO animals at weeks 52 and 60 in the males and at weeks 24, 48, 52, and 56 in the females (P< .05) The transient greater radial length and lower bone-cortex thickness observed in the treated cats were compensated for at the end of growth with no adverse clinical effects being observed. In conclusion, acyline as a contraceptive did not evidence a permanent or severe effect on domestic-cat growth.

Doppler ultrasonographic evaluation of medically treated female dogs with cystic endometrial hyperplasia-pyometra complex.

Monitoring the treatment outcome of canine cystic endometrial hyperplasia-pyometra complex (CEH-P) is essential to identify nonresponding patients who might require a rapid intervention to avoid life-threatening conditions. Uterine artery Doppler characterization may contribute to monitoring medically treated CEH-P, but published studies are currently lacking. Therefore, the aim of this longitudinal prospective observational study was to evaluate uterine artery resistance changes in the medical treatment of female dogs with CEH-P. Twelve diestrous female dogs suffering from CEH-P were treated with a combined protocol of cabergoline, cloprostenol, and antibiotics. The animals were clinically and ultrasonographically evaluated before the beginning of treatment (day 0) and on days 3, 7, 14, 21, and 28. The widest transverse diameter and luminal diameter of uterine horns were measured, as well as the peak systolic velocity (PSV) and end diastolic velocity (EDV) of uterine arteries. The resistance index (RI), pulsatility index (PI), and notch deep index (NDI) were calculated. On day 3, nine of 12 animals showed clinical improvement. In all these female dogs, the widest transverse sectional diameter (P < 0.01), luminal diameter (P < 0.01), PSV (P < 0.01), and EDV (P < 0.01) progressively decreased, while RI (P < 0.01), PI (P < 0.01), and NDI (P < 0.01) increased up to day 21. In nonresponding dogs (3/12), Doppler parameters remained unchanged. Although comparisons of PSV, EDV, and NDI were significantly different, these results should be cautiously interpreted due to the low statistical power. female dogs that responded to this treatment showed an increase in uterine artery resistance, along with clinical and ultrasonographic improvement.

Ovarian and uterine two-dimensional and Doppler ultrasonographic changes in the feline peri-estrus period.

OBJECTIVES: The aim of this study was to evaluate two-dimensional and Doppler ultrasonographic changes of the ovary and uterus during estrus and the early post-estrus period in domestic cats. METHODS: Two-dimensional and Doppler ultrasonographic evaluations of the ovaries and uterus were performed in seven queens on days 1, 3 and 5 of estrus, and 5 days after estrus (AE5). RESULTS: On day 1, 5.4 ± 0.5 follicles of 2.1 ± 0.1 mm were detected progressively increasing in number and size up to day 5 and then decreased on AE5 (P <0.05). A maximum follicular diameter of 4.1 ± 0.1 mm was achieved on day 5. Both during and after estrus, the uterus was generally hypoechoic compared with the surrounding tissues and delineated by a thin hyperechoic line corresponding to the serosa. In some animals, the uterine layers were distinguished during and after estrus. The blood flow waveforms of the intraovarian and uterine arteries were characterized by a systolic peak and diastolic flow extending throughout the remainder of the cardiac cycle to the next systole. In the uterine artery waveforms, the early diastolic notch was mild or absent during most estrous observations. The resistance index of the intraovarian arteries decreased up to day 5, and then increased on AE5 (P <0.05). The resistance index of the uterine arteries was lower during estrus than in the post-estrus period (P <0.05). CONCLUSIONS AND RELEVANCE: It is concluded that in the domestic cat, follicular number and diameter as well as ovarian and uterine blood flow changed during and immediately after estrus. Doppler ultrasound proved suitable to evaluate the hemodynamic changes involved in the cyclic remodeling of ovarian and uterine tissues that occurs during and after follicular growth in domestic cats.

Fecal Progestins Differentiate Pregnant From Nonpregnant Early Luteal Bitches.

Considering the high perimplantation progesterone (P4) secretion that occurs in female domestic dogs, we hypothesize that fecal P4 concentrations distinguishes pregnant from nonpregnant early luteal bitches. The objective of this study was to compare fecal P4 metabolites in early pregnant vs. nonpregnant early luteal bitches. Eighteen 2-6 years of age, 5-15 kg, pure-bred bitches, that were followed up for breeding management, and 2 ovariectomized (OVX) bitches were included in this study. On pregnancy day 18-28, a single fecal sample was collected from each animal. Fecal samples were frozen at -20°C until analysis. Pregnancy diagnosis was carried out by ultrasonography on day 21. Fecal samples were also collected from the 2 OVX bitches. Fecal P4 metabolites were extracted as based on methods described by Brown et al. (2008) and, then, measured by an electrochemiluminescence immunoassay. Eleven bitches were pregnant (PREG) while 7 were non-pregnant (N-PR). Fecal P4 metabolites concentrations were 283.9 ± 60.4 and 102.7 ± 19.1 (ng/g; P < .05) for PREG and N-PR, respectively. Both values were higher than those of the OVX bitches (9.9±1.1; P < .05). This noninvasive technique to measure P4 metabolites in feces appears as a simple and noncostly alternative for early pregnancy diagnosis in the domestic dog. Further large scale studies are necessary before this test could be widely recommended.

Uterine two-dimensional and Doppler ultrasonographic evaluation of feline pyometra.

The aim of this study was to compare uterine two-dimensional and Doppler ultrasonographic parameters in queens suffering from pyometra from those in early pregnancy. Secondly, the effect of the presence of clinical signs of systemic illness on these parameters was also described. Fourteen post-oestrous queens, with uterine luminal content in the absence of embryos were included. According to their outcome (pyometra surgery or parturition), the queens were retrospectively assigned to one of the following groups: Pyometra (PYO; n = 7) or pregnant (PRG; n = 7). In all the queens, two-dimensional and Doppler ultrasound examinations of the uterus were performed. The presence or absence of clinical signs of systemic illness was recorded. The widest cross-sectional diameter (UD), uterine wall thickness (WT), uterine lumen contents (LC) and uterine artery resistance index (RI) were measured. Uterine horn diameter was higher in PYO group than in PRG group (p < 0.05), while WT (p > 0.1) and LC (p = 0.09) did not differ between groups. Values of RI for PYO and PRG groups were 0.61 ± 0.03 vs 0.53 ± 0.09 (p < 0.05), respectively. PYO cats suffering from clinical signs of systemic illness showed larger UD than those without signs (p < 0.01). It is concluded that two-dimensional and Doppler ultrasound might be useful to distinguish queens suffering from pyometra from those in early pregnancy. Secondly, the clinical signs of systemic illness were associated with a larger UD.

Development and proliferation of feline endometrial glands from fetal life to ovarian cyclicity.

In this study it was determined the progression of uterine gland development from late gestation to puberty in domestic felids. Cell proliferation patterns for luminal (LE), glandular epithelium (GE) as well as stroma (S) were also described. Twenty-four uteri from female kittens: 45 and 65 days of gestation and 1 to 5, 8, 12, 16, 20 and 24 weeks postnatally were obtained. Uterine cross-sections were submitted for routine histological and immunohistochemical quantification of proliferating cell nuclear antigen (PCNA) techniques. Although prenatal uteri presented no indication of adenogenesis, 1 week old uteri revealed an incipient budding of the LE. During the second week budding increased and a mild degree of tubulogenesis of the GE into the stroma was detected. From the third to fifth weeks coiling, branching and cross-sections of glands appeared. These latter findings were more evident in week 8 when GE began to penetrate through much of the S to week 24. PCNA immunostaining revealed that DNA synthesis decreased throughout the study in the 3 cell compartments; (P < 0.01). Luminal proliferation began prenatally, it maintained up to postnatal week 8 to markedly decrease to puberty (P < 0.01). From postnatal week 3 up to week 8, GE mitotic activity was elevated becoming low thereafter (P < 0.01). Stroma actively proliferated prenatally (P < 0.01), diminishing up to week 8 (P < 0.01) and again during the last weeks (P < 0.01) of the study. It was concluded that, in domestic felids, proliferation of LE begins prenatally, histological uterine adenogenesis commenced during the first postnatal week and both events concluded by postnatal weeks 5-8.

Disrupting effect of androgens in postnatal female domestic cats.

To test the hypothesis that in domestic cats, postnatal androgens induce sterility, the aims of this study were to describe the reproductive effects and the clinical safety of a postnatal administration of a long term release androgen in this species. Thirteen newborn littermate female kittens were randomly assigned to one of the following treatment groups within the first 24h of birth: testosterone enanthate 12.5mg sc (TE; n=8) or Placebo (PL; n=5). The animals were subsequently assessed for fecal sexual hormones until puberty was attained and subsequently when matings occurred. After 21 days, ovulation and gestation were diagnosed. All queens were subsequently ovario-hysterectomized. Fecal testosterone concentrations differed between the treatment groups throughout the study period (P<0.05) being greater during the first 2 postnatal weeks in those of the TE group (P<0.01). Fecal estradiol was not affected by treatment (P>0.1). While all the females were receptive during the pubertal estrus (P>0.1), two TE (2/8) compared with all (5/5) females of the PL group had ovulations (P<0.05). Only one (1/2) compared with three (3/5) of the queens of the TE and PL groups, respectively became pregnant. All kittens of the TE group had transient clitoral enlargement. Anovulatory TE-treated cats had no corpus luteum, and a significant diminution of the endometrial glands as well as of the height of the uterine epithelium. It is concluded that, in domestic cats, a single postnatal supra-physiological dose of testosterone caused a large proportion of queens to be anovulatory and there were also histological endometrial abnormalities that also occurred with this treatment that were accompanied by mild and transient side effects.

Postnatal exposure to a progestin does not prevent uterine adenogenesis in domestic dogs.

To assess the effects of a single supraphysiological postnatal administration of a progestogen on uterine glands in dogs, 10 females were randomly assigned to a medroxyprogesterone acetate 35 mg (MPA; n = 6) or placebo (n = 4) group within the first 24 h of birth. The safety of the treatment was also evaluated. A transient mild clitoris enlargement appeared in MPA-treated females. Microscopic postpubertal uterine assessment revealed the presence of uterine glands in all cases without significant differences in the area occupied by the glands per µm(2) of endometrium nor in the height of the uterine epithelium.

Treatment of canine pyometra with the gonadotropin-releasing hormone antagonist acyline: a case series.

To describe the effect of the third-generation gonadotropin-releasing hormone antagonist acyline in the treatment of 4 diestrous bitches with the cystic endometrial hyperplasia-pyometra complex. The 4 bitches were treated with 330 µg/kg of subcutaneous acyline on day 0 and antibiotics, and followed up for 2 weeks. One closed-cervix case showed cervical dilatation 36 hours after treatment, and all the 4 animals showed resolution of clinical signs starting on day 3 posttreatment. Ultrasonographic uterine diameters and luminal contents decreased in the bitches having high progesterone serum concentrations before treatment but not in those with low levels. Serum progesterone importantly decreased from high to basal concentrations in the 3 "ultrasonographically cured" animals. No local or systemic side effects related to the treatment were observed. The gonadotropin-releasing hormone antagonist acyline may have a promising place for the medical treatment of cystic endometrial hyperplasia-pyometra complex in dogs.

Ejaculation training, seminal alkaline phosphatase and semen preservation through cooling in a milk-based extender in domestic cats.

The purpose of this report is to describe (1) the training of domestic cats in ejaculation into an artificial vagina (AV), (2) alkaline phosphatase (AP) concentrations in whole ejaculates, and (3) the in vitro effect of a skimmed-milk plus egg yolk (SM-Y) extender on feline spermatozoa incubated at 4ºC. Five post-pubertal cats were trained to ejaculate into an AV three times a week for 20 mins in the presence of a teaser queen. Fifty AV-obtained ejaculates were macro- and microscopically assessed, and the AP therein measured by optimized colorimetry. Eighty AV-obtained ejaculates were pooled, diluted in SM-Y extender [80% (v/v) skimmed milk, 20% (v/v) egg yolk, and antibiotics], stored at 4°C and evaluated daily for 6 days. All the animals could be trained to ejaculate, although the interval up to the first AV ejaculation varied from 1.5 to 5.5 months (mean 3.9 months). The final performance at collection ranged from excellent to poor and was inversely related to the training period required in all cases. The mean AP concentration in whole ejaculates was 20,645.6 ± 4405U/l, which was not correlated with the concentration of spermatozoa. Most seminal parameters [(%); total (77 ± 2.3) and progressive (62.7 ± 3.4) motility, live sperm (91.8 ± 1.2), intact plasmalemma (83.5 ± 2.6), normal acrosomes (83.5 ± 2.6), pH (6.6 ± 0.0) and osmolarity (mOsm/l; 321 ± 5.2)], though decreasing during storage in the cold, remained within values compatible with in vivo fertilization for 2 days.

Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade.

Desmopressin (DDAVP) is a vasopressin peptide analog with hemostatic properties that has been successfully used during surgery in patients with bleeding disorders. Recently published experimental and clinical data indicate that perioperative administration of DDAVP can minimize spread and survival of residual mammary cancer cells. The central aim of this study was to explore the effect of perioperative DDAVP and its relation to histologic grade in bitches with locally advanced mammary carcinoma. Of the 32 dogs initially recruited, 28 intact bitches with mammary carcinoma tumors stage III or IV were ultimately included. These dogs were randomized to receive DDAVP at intravenous doses of 1 µg/kg (n=18) or saline solution as placebo (n=10). En bloc mastectomy of the affected gland(s) was performed. Tumor malignancy was graded by the method of Elston and Ellis into well-differentiated (grade 1), moderately differentiated (grade 2), or poorly differentiated (grade 3). DDAVP therapy significantly prolonged the disease-free survival (P<0.001) and overall survival (P<0.01) in bitches with grade 2 or 3 carcinomas compared with bitches in the control group. No significant difference in disease-free period or overall survival was found between treatment groups in bitches with grade 1 tumors. The present data suggest that DDAVP may be an excellent candidate as a surgical adjuvant in the management of aggressive cancers in small animals. More research in this field is warranted.

Inmunohistoquímica y expresión de receptores de estrógenos y progesterona en neoplasias mamarias malignas caninas en distintos estadios clínicos / Immunohistochemistry and expression of estrogen and progesterone receptors in canine malignant mammary tumors in different clinical stages

La técnica de inmunohistoquímica descrita por Walker y col. (1998) y Mote y col. (2001) es de utilidad para la determinación de receptores de estrógenos y de progesterona en tumores mamarios de la hembra canina. Existe bastante controversia respecto al porcentaje de receptores de estrógenos y de progesterona, con valor pronóstico o predictivo en tumores malignos caninos debido, muy probablemente, a la falta de uniformidad en criterios de inclusión de los casos en los estudios realizados. El presente trabajo se realizó en una población de 51 perras. Los tumores fueron escindidos quirúrgicamente mediante mastectomía de las glándulas afectadas. Para la determinación de receptores hormonales, se analizó la muestra con mayores características histológicas de malignidad de cada animal. Se contabilizó el porcentaje de células tumorales positivas para cada uno de los receptores (receptor de estrógeno alfa, receptor de estrógeno beta y receptores de progesterona) en los distintos estadios clínicos (I, II, II, IV). Se consideró positivo todo corte ³ 20% de células tumorales positivas para cada uno de los receptores. Se realizó una estadística descriptiva (media y error estándar) con los animales positivos para cada uno de los receptores en los distintos estadios clínicos. En línea con reportes de otros autores, más de la mitad de caninos portadores de tumores mamarios malignos expresaron receptores de estrógenos y de progesterona. Conociendo que el comportamiento biológico de una neoplasia varía con el estadio clínico del paciente, resulta interesante estudiar la expresión de los receptores en cada uno de éstos, en animales con neoplasias mamarias malignas. Adicionalmente, a este objetivo incluye la puesta a punto la de técnica de inmunohistoquímica para la determinación de receptores hormonales en la especie.

receptors in canine mammary tumors. There is considerable controversy regarding the percentage of estrogen and progesterone receptors that having prognostic or predictive value in malignant tumors in dogs because, most likely, the lack of uniform criteria for inclusion of cases. This study was conducted in a population of 51 female dogs. The tumors were surgically treated by mastectomy of the affected glands. For the determination of hormone receptors, the sample analyzed was showed higher histological malignancy features of each animal. It was counted the percentage of tumor cells positive for each of the receptors (estrogen receptor alpha, estrogen receptor beta and progesterone receptor) in animals in various clinical stages (I, II, III, IV). It was considered positive cut-off ³ 20% tumor cells positive for each of the recipients. It was conducted a descriptive statistics (mean and standard error) which positive animals for each of the receptors in different clinical stages. In line with reports of other authors, more than half of canine carriers of malignant mammary tumors expressed estrogen and progesterone receptors. Knowing that the biological behavior of cancer varies with the clinical stage of the animal, objective was to study the expression of receptors in each of the clinical stages in animals with malignant mammary tumors. Additionally, this includes the preparation of the immunohistochemical technique for the determination of hormone receptors in this species.

Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: a pilot study.

Desmopressin (1-deamino-8-d-arginine vasopressin, also known as DDAVP) is a safe haemostatic compound capable of inhibiting lymph node and lung metastasis in a mouse model of mammary tumour manipulation and surgical excision. The aim of this study was to test the efficacy and safety of perioperative DDAVP (1microg/kg) in surgically treated bitches with mammary gland tumours (MGT). Twenty-one, otherwise healthy, intact bitches, with malignant MGT stage III or IV were randomly allocated to DDAVP (n=11) or placebo (n=10) groups. En bloc mastectomy of the affected gland/s was performed. DDAVP had a significant beneficial effect on disease-free period (P<0.01) and overall survival time (P<0.05). No side effects were seen in any of the cases. Whatever the mechanism of action, it seems that DDAVP may have a novel use in cancer surgery to minimise spread or survival of residual malignant cells. Additional, large scale controlled trials are required to fully evaluate this adjuvant pharmacological protocol.

New GnRH analogs in canine reproduction.

Gonadotropin-releasing hormone (GnRH) analogs, which include agonists and antagonists, have been produced by amino acid substitutions of the native GnRH molecule to create greater potency and longer duration of effectiveness. The aim of this article was to review the pharmacological effects and the existing clinical literature of new GnRH analogs, namely agonists released from long-term formulations and third generation antagonists, in domestic dogs. Long-term administration of agonists functions through desensitization and down-regulation of GnRH pituitary receptors inhibiting gonadotropin production and release after an initial stimulation. Conversely, GnRH antagonists bind to gonadotrope GnRH receptors and compete successfully with endogenous GnRH for occupancy, thereby inhibiting the pituitary-gonadal axis immediately. There is a promising place for both agonists and antagonists in future canine reproduction. They can be used in the control of estrous cycle, hormone-dependent diseases as well as in contraception. Some information on the effectiveness and safety of these new analogs in canine reproduction is already available, yet further work is needed before they could be widely recommended. The increase in gonadotropins and gonadal steroids following administration of agonists might have adverse effects when used on hormone-dependent diseases. This initial "flare" should also be carefully managed in anestrous and prepubertal bitches. At present, the main application of antagonists seems limited to situations where an acute endocrine, inhibitory effect is required, e.g. proestrus or pregnancy termination. Future commercial availability of long-acting, single-dose antagonists could go far towards controlling pet population.

Shortening of interestrous intervals with cabergoline in bitches: a clinical trial.

Two consecutive interestrous intervals (n=46) were recorded in 23 bitches of different breeds. At varying times after day 100 from the onset of the second proestrus, cabergoline (5 microg/kg per os q 24 hours) was administered from early (n=11), mid- (n=10), and late (n=2) anestrus until 2 days after the beginning of the following proestrus. Interestrous intervals (IEI) were significantly shorter in the cabergoline-treated time periods when compared to the nontreated IEI (184+/-4.5 days versus 239+/-4.5 days; P<0.01). The mean number of days of cabergoline treatment until the onset of proestrus was 21.4+/-2.9 (least square means and standard error of the mean [LSM+/-SEM]). Mean cabergoline treatment durations beginning in early, mid-, and late anestrus were 27.4+/-3.7, 17.6+/-3.8, and 5+/-3 days (LSM+/-SEM), respectively. A significant correlation was found between the stage of anestrus in which the treatments began and the duration of the treatments required to induce estrus (0.51, P=0.01).

Enanismo pituitario canino: reporte de un caso / Canine pituitary dwarfism: a report of one case

El enanismo pituitario es una endocrinopatía ocasionada por la deficiencia de hormona de crecimiento. La imposibilidad de medir esta hormona en los caninos ha ocasionado que, muchas veces, no se considere al enanismo pituitario entre los diagnósticos diferenciales de retraso del crecimiento y dermatopatía en el cachorro. En el presente trabajo se describen dos casos clínicos de esta enfermedad en caninos, los cuales una vez referidos a la Facultad de Ciencias Veterinarias de La Plata, Argentina, se confirmó el diagnóstico de enanismo pituitario. La posibilidad de dosificar la hormona de crecimiento canina mediante radioinmunoensayo origina perspectivas alentadoras en el conocimiento, de la prevalencia de esta enfermedad en los caninos

A study of two protocols combining aglepristone and cloprostenol to treat open cervix pyometra in the bitch.

To compare the efficacy and safety of two protocols using a combination of aglepristone and cloprostenol for the treatment of open cervix pyometra in the bitch and to describe the progesterone (P4) serum profiles before and during treatments, 15 bitches were randomly allocated into two treatment groups: I (n = 8): aglepristone was administered at 10mg/kg, s.c., on Days 1, 3, 8, and 15 (if not cured), combined with cloprostenol at the dose of 1 microg/kg, s.c., on Days 3 and 8, and II (n = 7): received the same treatment with aglepristone as Treatment I but cloprostenol on Days 3, 5, 8 10, 12, and 15 (if not cured). Before the beginning of the treatments and then on Days 8, 15, and 29 all bitches were evaluated for clinical signs, side effects, hemogram, serum P4 concentrations, and uterus diameters. Bitches in both treatment groups, with (n = 6) or without (n = 9; > or =1.2 ng/ml) initial basal P4 serum concentrations, achieved treatment success without side effects and no significant differences, either on Day 15 (6/8 for Treatment I and 4/7 for Treatment II) or on Day 29 (2/8 for Treatment I and 3/7 for Treatment II). In both treatments groups, clinical signs, blood parameters, and uterine diameters improved to normal values throughout the experiments. A significant interaction between day and treatment was found for percentage change in P4 when all bitches were considered together. Redevelopment of pyometra in the next estrous cycle occurred in 20% of the bitches. One nonrecurrent bitch was mated and whelped a normal litter. It is concluded that these two combined protocols proved to be efficient and safe in reversing clinical signs of open cervix pyometra independently of initial P4 concentrations and that the number of cloprostenol administrations seemed to have an effect on P4 serum changes throughout treatments.

Use of cabergoline to treat primary and secondary anestrus in dogs.

OBJECTIVE: To determine whether cabergoline would be safe and effective for induction of estrus in dogs with primary or secondary anestrus. DESIGN: Prospective case series. ANIMALS: 6 privately owned otherwise healthy pure-bred dogs with primary or secondary anestrus. PROCEDURE: Dogs were treated with cabergoline (5 microg/kg [2.3 microg/lb], p.o., q 24 h) until 2 days after the onset of proestrus. Follicular development was assessed by means of cytologic examination of vaginal smears; ovulation was assessed by measuring serum progesterone concentration 3 weeks after the onset of estrus. Five bitches were mated during behavioral estrus. RESULTS: All dogs had normal estrus periods, and all 5 dogs that were mated whelped normal litters. Mean duration of cabergoline treatment was 16 days. None of the dogs had any adverse effects associated with cabergoline administration. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that administration of cabergoline is safe and effective for treatment for primary and secondary anestrus in dogs.

Serum and seminal markers in the diagnosis of disorders of the genital tract of the dog: a mini-review.

Serum and seminal biologic substances that are produced either by normal or abnormal tissues of the organism and that can be used to diagnose pathological conditions are usually referred as markers. The aim of this article is to briefly review the most relevant clinical features of the main genital markers in the male dog: alkaline phosphatase (AP), carnitine and canine prostate-specific arginine esterase (CPSE). Carnitine and AP are markers for the presence of epididymal fluid in the ejaculate and their measurement in azoospermic dogs has been used as an indicator of tubular patency of the ductal network. Although AP is not present in high concentrations in the testis, this does not preclude the possibility that testicular cells might secrete some AP. If this were true, AP could also reflect, at least in some degree, germ cell function in this species. Prostate-specific arginine esterase, the major secretory product of the canine prostate, is a known marker of gland secretion in the dog. Tumor markers frequently used in human medicine, such as prostatic acid phosphatase and prostate-specific antigen, are is still controversial in the diagnosis of prostatic carcinoma of the dog. Although further research is necessary to define the exact role of CPSE, it seems to be a promising diagnostic tool in nonneoplasic canine prostatic disorders. Future studies should also address the quantitative relationship among serum and prostatic androgen levels, prostatic androgen-dependent problems and how these are affected by anti-androgen treatment. The aim of this article is to briefly review the most relevant clinical features of three main genital markers of the male dog.